BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22241900)

  • 1. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
    Mercer LK; Green AC; Galloway JB; Davies R; Lunt M; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2012 Jun; 71(6):869-74. PubMed ID: 22241900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF; Michaud K; Wolfe F
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.
    Raaschou P; Simard JF; Asker Hagelberg C; Askling J;
    BMJ; 2016 Jan; 352():i262. PubMed ID: 26823527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Galloway JB; Mercer LK; Moseley A; Dixon WG; Ustianowski AP; Helbert M; Watson KD; Lunt M; Hyrich KL; Symmons DP
    Ann Rheum Dis; 2013 Feb; 72(2):229-34. PubMed ID: 22532633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
    Davies R; Galloway JB; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Oct; 70(10):1831-4. PubMed ID: 21784722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.
    Závada J; Lunt M; Davies R; Low AS; Mercer LK; Galloway JB; Watson KD; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2014 Jan; 73(1):252-5. PubMed ID: 23644671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
    Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Ustianowski AP; Helbert M; Watson KD; Lunt M; Symmons DP;
    Ann Rheum Dis; 2011 Oct; 70(10):1810-4. PubMed ID: 21784730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
    Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
    Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
    Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.
    Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Fu B; Ustianowski AP; Watson KD; Lunt M; Symmons DP; ;
    Rheumatology (Oxford); 2011 Jan; 50(1):124-31. PubMed ID: 20675706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.
    Wang JL; Yin WJ; Zhou LY; Zhou G; Liu K; Hu C; Zuo XC; Wang YF
    Clin Rheumatol; 2020 Mar; 39(3):769-778. PubMed ID: 31823140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
    Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP;
    Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
    Mercer LK; Davies R; Galloway JB; Low A; Lunt M; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2013 Jan; 52(1):91-8. PubMed ID: 23238979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors.
    van Lümig PP; Menting SP; van den Reek JM; Spuls PI; van Riel PL; van de Kerkhof PC; Fransen J; Kievit W; de Jong EM
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):752-60. PubMed ID: 25229823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
    Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Iannone F; Zavada J; Morel J; Gottenberg JE; Hyrich KL; Listing J
    Ann Rheum Dis; 2017 Feb; 76(2):386-391. PubMed ID: 27307502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.